




仁愛醫療財團法人  
*JEN-AI HOSPITAL*

# 小細胞肺癌診療指引

2009年06月03日制定  
2010年03月16日一修  
2011年04月20日二修  
2012年04月18日三修  
2013年03月20日四修  
2014年02月19日五修  
2015年02月26日六修  
2016年02月17日七修  
2017年02月15日八修  
2018年02月21日九修  
肺癌醫療團隊共同制定


# 修訂原則

- **參與修訂科別:**胸腔內科、放射診斷科、病理科、腫瘤治療科、血液暨腫瘤內科、安寧緩和團隊。
- **診療指引需符合以下原則：**
  - 一、依據實證醫學精神，並於指引中註明主要參考文獻（至少為 peer review article，若引用醫院之資料庫資料需提供分析及討論紀錄。
  - 二、參酌國情並經院內共識討論，且有相關會議紀錄佐。
  - 三、定期檢視改版（至少每年一次，且明確標示制訂或修訂日期）。
  - 四、團隊共識後所訂之指引，應提送癌委會核備後公告。




SCLC stages :

- (1)Limited -stage disease : disease confined to the ipsilateral hemithorax,which can be safely encompassed within a radiation field.  
(T any, N any, M0, except T3-4 due to multiple lung nodules that do not fit in a tolerable radiation field)
- (2)Extensive-stage disease : disease beyond ipsilateral hemithorax,including malignant pleural or pericardial effusion or hematogenous metastases.  
(T any, N any,M1a/b ; T3-4 due to multiple lung nodules)



Response assessment	Following initial evaluation	Adjuvant Treatment	Surveillance
---------------------	------------------------------	--------------------	--------------



<b>(SCLC) 小細胞肺癌化療處方 Chemotherapy regimen</b>		
治療目的	組套編碼	處方內容
Limited stage  CCRT	SCLCRT1	<b>Etoposide/Cisplatin/RT<sup>42</sup></b> Etoposide 100mg/m <sup>2</sup> /day,in NS 500 mL,IV over 1 hour,days 1-3 Cisplatin 80 mg/m <sup>2</sup> ,in NS 300 mL,IV over 2 hour,day 1 Repeat every28 days concurrent with Thoracic RT Note: * Radiotherapy 1.8Gy once daily to 55-61 Gy or 1.5Gy twice daily to 45Gy *The use of G-CSF is not recommended during concurrent chemotherapy plus radiotherapy. *Radiotherapy for limited stage disease should start with cycle 1 or 2 of chemotherapy.
	SCLCRT2	<b>Etoposide/Carboplatin /RT<sup>26</sup></b> Etoposide 100 mg/m <sup>2</sup> /day,in NS 500 mL,IV over 2 hour,days 1-3 Carboplatin AUC 6 in NS 250 mL,IV over 60 minutes,day1 Repeat every 21 days
Limited stage  Chemotherapy	SCLCFL01	<b>EP/RT(Etoposide/Cisplatin/RT)<sup>42</sup></b> Etoposide 100 mg/m <sup>2</sup> , in NS 500 mL IV over 1 hour, days 1-3 Cisplatin 80 mg/m <sup>2</sup> , in NS 300 mL IV over 2 hours, day 1 Repeat every 28 days
	SCLCFL02	<b>Etoposide/Carboplatin <sup>26</sup></b> Etoposide 100 mg/m <sup>2</sup> , in NS 500 mL IV over 2 hour, days 1-3 Carboplatin AUC 6, in NS 250 mL IV over 60 min, day 1 Repeat every21 days
Extensive stage  Chemotherapy	SCLCFL03	<b>EP(Etoposide/Cisplatin)<sup>43</sup></b> Etoposide 80 mg/m <sup>2</sup> , in NS 500 mL IV over 1 hour, days 1-3 Cisplatin 80 mg/m <sup>2</sup> , in NS 300 mL IV over 2 hours, day 1 Repeat every 21 days

	SCLCFL04	<b>Etoposide/Carboplatin<sup>44</sup></b> Etoposide 100 mg/m <sup>2</sup> , in NS 500 mL IV over 1 hour, days 1-3 Carboplatin AUC 5-6, in NS 250 mL IV over 60 min, day 1 Repeat every 28 days
	SCLCFL05	<b>Irinotecan/Cisplatin<sup>15,45</sup></b> Irinotecan 65 mg/m <sup>2</sup> , in NS 250 mL IV over 90 minutes, days 1, 8 Cisplatin 30 mg/m <sup>2</sup> , in NS 300 mL IV over 1 hours, day 1,8 Repeat every 21 days
	SCLCFL06	<b>Irinotecan/Carboplatin<sup>15,46</sup></b> Irinotecan 50 mg/m <sup>2</sup> , in NS 250 mL IV over 30 min, day1,8,15 Carboplatin AUC 5, IV over 60 min, days 1 Repeat every 28 days
Second-line/ Relapse disease	SCLCSL01	<b>Topotecan<sup>8,31,47</sup></b> Topotecan 1.5 mg/m <sup>2</sup> /day, in NS 100 ml IV over 30min, days 1-5 Repeat cycle every 21days
	SCLCSL02	<b>Paclitaxel<sup>24,33</sup></b> Paclitaxel 80 mg/m <sup>2</sup> in NS 500 ml IV over 1 hour, day 1 weekly for 6wk then rest 2Wk Repeat every 8wk
	SCLCSL03	<b>Cyclophosphamide/Doxorubicin/vincristine<sup>48</sup></b> Doxorubicin 45 mg/m <sup>2</sup> IV over 10 min, day 1 vincristine 2 mg/m <sup>2</sup> IV over 10 min , day 1 Cyclophosphamide 1000mg/m <sup>2</sup> in NS 100 ml IV over 30 min, day 1 Repeat every 21-28d
	SCLCSL04	<b>Docetaxel<sup>27</sup></b> Docetaxel 100 mg/m <sup>2</sup> in NS 250 ml IV over 1 hour, day1 Repeat cycle every 21 days

SCLCSL05	<b>Gemcitabine</b> <sup>14,48</sup> Gemcitabine 1000 mg/m <sup>2</sup> in NS 100 ml IV over 30 min, days 1, 8, and 15 Repeat every 28-days
SCLCSL06	<b>Temozolomide</b> <sup>20,49</sup> Temozolomide 75 mg/m <sup>2</sup> /day, PO, days 1-21 Repeat every 28 days <sup>20</sup>
SCLCSL07	<b>Etoposide</b> <sup>11,50</sup> Etoposide 50 mg/m <sup>2</sup> /day, PO, days 1-21 Repeat every 28days <sup>11</sup>
SCLCSL08	<b>Irinotecan</b> <sup>51</sup> Irinotecan 100 mg/m <sup>2</sup> , in NS 250 mL IV over 90 min weekly
SCLCSL09	<b>Vinorelbine</b> <sup>52</sup> Vinorelbine 30 mg/m <sup>2</sup> in NS 50 ml IV 10 minutes, weekly
	<b>Nivolumab ± ipilimumab</b> <sup>55</sup> Nivolumab 3mg/kg every 2 weeks or Nivolumab plus ipilimumab 1 mg/kg plus 3 mg/kg every 3 weeks



## (SCLC) 小細胞肺癌 Radiation therapy

Treatment type	RT technique	Total dose	Fraction size / # Fractions
Limited stage <sup>4,12</sup>	Conventionally Fractionated RT (IMRT)	45Gy to mediastinum <sup>28</sup> 50-65Gy to primary tumor 70Gy for boosting gross tumor	1.8-2Gy/ fraction
Prophylactic cranial irradiation <sup>29,30</sup>	Hypofractionated RT	25Gy to Whole brain	In 10 daily fractions
	Conventionally Fractionated RT	30.6Gy to Whole brain	1.8Gy/ fraction

註：實際治療分次劑量 × 總治療次數，應與處方劑量差異在±1Gy 內。

註：放射治療詳細流程請參照 肺癌放射治療標準政策與執行規範。